Skip to content

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women: RESOLVE-SEX

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05597098
Acronym
RESOLVE-SEX
Enrollment
34
Registered
2022-10-27
Start date
2022-12-12
Completion date
2027-12-12
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Brief summary

Important differences exist between sexes in incidence, disease patterns and outcomes in coronary artery disease that is not well understood. It is likely that key differences in the underlying biological mechanism, in particular in inflammatory responses, play a part in underpinning these differences. Previous evidence demonstrates that healthy females appear to be more adept at resolving inflammation compared to healthy males. Since inflammation is thought to be a key initiating phenomenon in coronary artery disease the investigators will examine the differences in inflammatory resolution between the sexes in healthy volunteers.

Detailed description

Inflammation is a key process in triggering events caused by coronary artery disease. Indeed, large scale trials have tested the efficacy of a range of anti-inflammatory approaches. However, whilst some of these confirmed the utility of such approaches in leading to reductions in coronary artery disease; the benefits came at a cost with an increased risk of infection. In their previous work the investigators discovered that, women demonstrate enhanced resolution of inflammation compared to males. This accelerated resolution coincided with improved blood vessel function and health. It is also now accepted that a failure of resolution plays an important part in the enhanced inflammation seen in coronary artery disease. Whether the differences in the incidence of coronary artery disease between men and women might be related to differences in their capacity to mount a resolution response is unknown. To determine whether inflammatory resolution differs between sexes the investigators will use the validated cantharidin-induced model of acute inflammation in healthy volunteers. Previous published studies have shown when cantharidin is applied to the skin it causes acantholysis and blister formation. It is a safe, reproducible technique with no permanent scarring or ill-effects. The investigators will study the effects on inflammatory responses by measuring the levels of cells, inflammatory mediators and markers of vascular function in blister fluid, urine, saliva and blood. Cantharidin application will be applied to separate areas of the skin over the course of three days to create three small blisters in order to examine different timepoints of the inflammatory process. The blister fluid will then be collected on the fourth day which will be analysed according to standard laboratory techniques including flow cytometry.

Interventions

0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.

Sponsors

Queen Mary University of London
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy male and female volunteers 2. Aged 18-45 3. Volunteers who are willing to sign the consent form

Exclusion criteria

1. Healthy subjects unwilling to consent 2. Pregnant, or any possibility that a subject may be pregnant unless in the latter case a pregnancy test is performed with a negative result 3. Current breast feeding 4. History of any serious illnesses, including recent infections or trauma 5. Subjects taking systemic medication (other than the oral contraceptive pill) 6. Subjects with recent (2 weeks) or current antibiotic use 7. Subjects with any history of a blood-borne infectious disease such as Hepatitis B or C virus, or HIV

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the presence or not of blister at each timepoint over 24-72h between the sexes24 hours, 48 hours, 72 hoursVisual inspection as to the presence of an intact blister of 24hr, 48 hr and 72 hr cantharidin blisters
Comparison of blister volume at each timepoint over 24-72h between the sexes24 hours, 48 hours, 72 hoursBlister fluid sampled and weighed to determine volume
Comparison of blister cell number at each timepoint over 24-72 hours between the sexes24 hours, 48 hours, 72 hoursBlister fluid collected from 24 hour, 48 hour and 72 hour cantharidin blisters. Fluid will be analysed using standard laboratory techniques including labelled flow cytometry

Secondary

MeasureTime frameDescription
Comparison of blister leukocyte subsets (neutrophil and monocyte) between the sexes at each timepoint24 hours, 48 hours, 72 hoursBlister fluid collected from 24 hour, 48 hour and 72 hour cantharidin blisters. Fluid will be analysed using standard laboratory techniques including labelled flow cytometry
4. Comparison of markers of blister efferocytosis between the sexes at each timepoint24 hours, 48 hours, 72 hoursBlister fluid collected from 24 hour, 48 hour and 72 hour cantharidin blisters. Fluid will be analysed using standard laboratory techniques including labelled flow cytometry
Comparison of blister lactate levels and LDH between the sexes at each timepoint24 hours, 48 hours, 72 hoursBlister fluid collected from 24 hour, 48 hour and 72 hour cantharidin blisters. Analysis as per standard laboratory techniques.
Comparison of cell death, necrotic, and apoptotic cell numbers between the sexes at each timepoint24 hours, 48 hours, 72 hoursBlister fluid collected from 24 hour, 48 hour and 72 hour cantharidin blisters. Fluid will be analysed using standard laboratory techniques including labelled flow cytometry

Countries

United Kingdom

Contacts

Primary ContactAmrita Ahluwalia, BSc PhD
a.ahluwalia@qmul.ac.uk0207 882 8377
Backup ContactAndrew J Sullivan, MBBS BSc
a.j.sullivan@qmul.ac.uk020 7882 8931

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026